MCID: MCN001
MIFTS: 49

Mucinous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 12 15 70
Mucin-Producing Adenocarcinoma 12 70
Pseudomyxoma Peritonei with Unknown Primary Site 12
Mucin-Secreting Adenocarcinoma 12
Mucin-Secreting Carcinoma 12
Adenocarcinoma, Mucinous 44
Mucous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3030
MeSH 44 D002288
SNOMED-CT 67 72495009 900006
UMLS 70 C0007130 C0334368

Summaries for Mucinous Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to appendix adenocarcinoma and endometrial mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is CHST4 (Carbohydrate Sulfotransferase 4), and among its related pathways/superpathways are ERK Signaling and Endometrial cancer. The drugs Oxaliplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and appendix, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 737)
# Related Disease Score Top Affiliating Genes
1 appendix adenocarcinoma 33.1 KRT7 KRT20 KRAS CDX2
2 endometrial mucinous adenocarcinoma 32.8 PGR MUC1 CDKN2A
3 cervical adenoma malignum 32.5 TP53 PGR KRT7 CDX2
4 bile duct mucinous adenocarcinoma 32.4 TP53 MUC5AC MUC1
5 ovarian mucinous adenocarcinoma 32.4 MUC5AC KRT7 KRT20 CEACAM5 CDX2
6 mucinous stomach adenocarcinoma 32.2 NKX2-1 KRT7 CDX2
7 pseudomyxoma peritonei 31.6 TP53 MUC5AC MUC1 KRT7 KRT20 KRAS
8 urachal adenocarcinoma 31.4 KRAS CEACAM5
9 intestinal obstruction 30.9 KRT7 KRT20 CEACAM5 CDX2
10 anus adenocarcinoma 30.8 MUC5AC KRT7 CDX2
11 rectum cancer 30.8 MLH1 KRT20 KRAS CEACAM5
12 clear cell adenocarcinoma 30.7 TP53 KRT7 KRT20
13 bladder adenocarcinoma 30.6 KRT7 KRT20 ERBB2 CDX2
14 mucinous lung adenocarcinoma 30.6 NRG1 NKX2-1 KRAS
15 sertoli-leydig cell tumor 30.6 PGR MUC1 KRT7
16 anal canal adenocarcinoma 30.5 MUC5AC KRT7 KRT20 CEACAM5 CDX2
17 teratoma 30.5 TP53 NKX2-1 KRT7 KRT20 KRAS CEACAM5
18 vaginal discharge 30.5 PGR ESR1 CEACAM5
19 transverse colon cancer 30.5 MLH1 KRT7 KRT20 KRAS CEACAM5
20 adenocarcinoma in situ 30.4 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
21 neuroendocrine carcinoma 30.4 NKX2-1 MUC1 KRT7 KRT20 CEACAM5
22 mucinous cystadenocarcinoma 30.4 MUC1 KRT7 KRT20 CEACAM5
23 lymphangitis 30.4 NKX2-1 CEACAM5 ALK
24 cystic teratoma 30.4 TP53 NKX2-1 MUC5AC KRT7 KRT20 KRAS
25 cystadenoma 30.4 PGR MUC5AC MUC1 KRT7 KRT20 CEACAM5
26 eyelid carcinoma 30.3 KRT7 KRT20
27 mature teratoma 30.3 TP53 KRT7 KRAS ERBB2 CEACAM5
28 jejunal neoplasm 30.3 KRT7 KRT20
29 gastrointestinal carcinoma 30.3 TP53 MUC1 KRT20 CEACAM5 CDX2
30 descending colon cancer 30.3 KRAS CEACAM5 CDX2
31 bile duct cysts 30.3 KRT7 KRAS CEACAM5
32 eccrine papillary adenocarcinoma 30.3 PGR KRT7 CEACAM5
33 thymus adenocarcinoma 30.3 KRT20 CEACAM5 CDX2
34 gallbladder adenocarcinoma 30.3 TP53 KRT20 ERBB2 EGFR
35 ovarian large-cell neuroendocrine carcinoma 30.3 KRT7 KRT20
36 adenosquamous colon carcinoma 30.3 MLH1 KRT7 CDX2
37 ovarian germ cell cancer 30.3 NKX2-1 KRT7 CEACAM5
38 serous cystadenocarcinoma 30.3 TP53 PGR KRAS ERBB2
39 horseshoe kidney 30.3 NKX2-1 KRT7 KRT20 EGFR CDX2
40 benign mesothelioma 30.3 NKX2-1 KRT7 KRT20 CEACAM5 CDKN2A
41 ovarian mucinous neoplasm 30.3 MUC5AC KRT7 KRT20 KRAS CEACAM5 CDX2
42 adenocarcinoma 30.3 TP53 NKX2-1 MUC1 MLH1 KRT7 KRT20
43 adenoma 30.2 TP53 MUC5AC MUC1 MLH1 KRT7 KRT20
44 mammary analogue secretory carcinoma 30.2 TP53 MUC1 EGFR
45 krukenberg carcinoma 30.2 KRT7 KRT20 CEACAM5 CDX2
46 cystadenocarcinoma 30.2 TP53 PGR MUC5AC MUC1 KRT7 ERBB2
47 pancreatic adenocarcinoma 30.1 TP53 KRAS ERBB2 EGFR CDKN2A
48 mammary paget's disease 30.1 PGR MUC1 KRT7 KRT20 ESR1 ERBB2
49 prostatic hypertrophy 30.1 PGR ESR1 EGFR
50 benign teratoma 30.1 TP53 NKX2-1 MUC1 KRT7 KRT20 CEACAM5

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.92 EGFR KRAS
2 Decreased viability GR00055-A-2 9.92 EGFR KRAS
3 Decreased viability GR00055-A-3 9.92 KRAS
4 Decreased viability GR00106-A-0 9.92 KRAS
5 Decreased viability GR00221-A-1 9.92 ALK CDKN2A EGFR ESR1 KRAS
6 Decreased viability GR00221-A-2 9.92 ESR1 KRAS
7 Decreased viability GR00221-A-3 9.92 CDKN2A ERBB2
8 Decreased viability GR00221-A-4 9.92 ALK CDKN2A EGFR ESR1 ERBB2
9 Decreased viability GR00249-S 9.92 ALK
10 Decreased viability GR00301-A 9.92 KRAS
11 Decreased viability GR00381-A-1 9.92 KRAS
12 Decreased viability GR00386-A-1 9.92 ESR1
13 Decreased viability GR00402-S-2 9.92 ESR1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 CDKN2A CDX2 CHST4 EGFR ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.3 ALK CDKN2A CDX2 EGFR ERBB2 ESR1
3 endocrine/exocrine gland MP:0005379 10.26 ALK CDKN2A CDX2 EGFR ERBB2 ESR1
4 digestive/alimentary MP:0005381 10.21 CDKN2A CDX2 EGFR ERBB2 ESR1 KRAS
5 embryo MP:0005380 10.15 CDKN2A CDX2 EGFR ERBB2 ESR1 HNF4A
6 neoplasm MP:0002006 10.11 ALK CDKN2A CDX2 EGFR ERBB2 ESR1
7 integument MP:0010771 10.09 ALK CDKN2A EGFR ERBB2 ESR1 KRAS
8 normal MP:0002873 9.96 ALK CDX2 EGFR ERBB2 ESR1 HNF4A
9 limbs/digits/tail MP:0005371 9.95 CDX2 EGFR ERBB2 ESR1 KRAS PGR
10 reproductive system MP:0005389 9.9 ALK CDKN2A CDX2 EGFR ERBB2 ESR1
11 no phenotypic analysis MP:0003012 9.87 CDKN2A EGFR ESR1 KRAS NKX2-1 PGR
12 respiratory system MP:0005388 9.61 ALK CDKN2A EGFR ERBB2 ESR1 KRAS
13 skeleton MP:0005390 9.32 ALK CDKN2A CDX2 EGFR ERBB2 ESR1

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
7
Camptothecin Experimental Phase 3 7689-03-4
8
Edrecolomab Experimental, Investigational Phase 3 156586-89-9
9
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
10 Micronutrients Phase 3
11 Trace Elements Phase 3
12 Carotenoids Phase 3
13 Adjuvants, Immunologic Phase 3
14 Immunosuppressive Agents Phase 3
15 Antimetabolites Phase 3
16 Hematinics Phase 3
17 Anti-Infective Agents Phase 3
18 Antiviral Agents Phase 3
19 taxane Phase 3
20
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
21
Nintedanib Approved Phase 2 656247-17-5 56843413
22
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
23
Iodine Approved, Investigational Phase 2 7553-56-2 807
24
Ipilimumab Approved Phase 2 477202-00-9
25
nivolumab Approved Phase 2 946414-94-4
26
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
27
Turmeric Approved, Experimental, Investigational Phase 2
28
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
29
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
30
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
31
Pembrolizumab Approved Phase 2 1374853-91-4
32
Olaparib Approved Phase 2 763113-22-0 23725625
33
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
34
Durvalumab Approved, Investigational Phase 2 1428935-60-7
35
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
36
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
37
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
38
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
39
leucovorin Approved Phase 2 58-05-9 6006
40
Indomethacin Approved, Investigational Phase 1, Phase 2 53-86-1 3715
41
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
42
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
44
Cediranib Investigational Phase 2 288383-20-0 9933475
45
Maleic acid Experimental Phase 2 110-16-7 444266
46 Fluorodeoxyglucose F18 Phase 2
47 Radiopharmaceuticals Phase 2
48 Immunoglobulin Fc Fragments Phase 2
49 Pharmaceutical Solutions Phase 2
50
Apatinib Phase 1, Phase 2 811803-05-1

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
3 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
4 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
5 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
6 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
7 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
8 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
9 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
10 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
11 A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer. Unknown status NCT01814501 Phase 2 irinotecan hydrochloride;fluorouracil;leucovorin calcium
12 A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT01652196 Phase 2 oxaliplatin;leucovorin;fluorouracil
13 Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks? Unknown status NCT01037049 Phase 2
14 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
15 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
16 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
17 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
18 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
19 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
20 A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) Recruiting NCT04446091 Phase 1, Phase 2 Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.);Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
21 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
22 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
23 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
24 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
25 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
26 Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer Active, not recruiting NCT01871571 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
27 A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer Active, not recruiting NCT00745134 Phase 2 Capecitabine
28 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Active, not recruiting NCT00492778 Phase 2 Cisplatin
29 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
30 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
31 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
32 A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor MEDI4736 (Durvalumab) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or MEDI4736 (Durvalumab) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Not yet recruiting NCT04739800 Phase 2 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
33 Injection of Bromelain and Acetylcysteine in Combination Into Recurrent Mucinous Tumour or Pseudomyxoma Peritonei Not yet recruiting NCT03976973 Phase 1, Phase 2 Bromelain, Stem;Acetylcysteine
34 Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer Terminated NCT00002796 Phase 1, Phase 2 fluorouracil;sodium phenylbutyrate;indomethacin
35 A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer Terminated NCT00052585 Phase 2 irinotecan hydrochloride;gefitinib;leucovorin calcium;fluorouracil
36 Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease Terminated NCT01285102 Phase 2
37 Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer Withdrawn NCT02235324 Phase 2 leucovorin calcium;fluorouracil
38 A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer Completed NCT00060411 Phase 1 erlotinib hydrochloride;fluorouracil;leucovorin calcium;oxaliplatin
39 Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer Completed NCT01923337 Phase 1 irinotecan hydrochloride;alisertib
40 Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma Completed NCT00003799 Phase 1 fluorouracil;oxaliplatin;leucovorin calcium
41 Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
42 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
43 A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies Completed NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
44 Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors Recruiting NCT03476681 Phase 1 NEO-201
45 Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies Recruiting NCT04088786 Phase 1 nanoliposomal irinotecan
46 A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients Active, not recruiting NCT02232152 Phase 1 6,8-bis(benzylthio)octanoic acid;fluorouracil
47 Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer Active, not recruiting NCT02270606 Phase 1 fluorouracil;oxaliplatin;leucovorin calcium
48 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
49 A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Suspended NCT04092270 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride;Peposertib
50 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Suspended NCT02020707 Phase 1 Nab-paclitaxel

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

40
Lung, Colon, Appendix, Prostate, Ovary, Liver, Cervix

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 2353)
# Title Authors PMID Year
1
Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content. 61
33571895 2021
2
Development of a mucinous adenocarcinoma on a sigmoid colpoplasty for vaginal agenesis: About a case report and review of the literature. 61
33786358 2021
3
Colorectal cancer under 20 years old: a retrospective analysis from three tertiary hospitals. 61
32968876 2021
4
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component. 61
33331169 2021
5
Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. 61
33024306 2021
6
Mucinous adenocarcinoma caused by cancerization from a ciliated multinodular papilloma tumor: A case report. 61
33811447 2021
7
Snowball-like appearance on radial endobronchial ultrasonography in a patient with invasive mucinous adenocarcinoma. 61
33732468 2021
8
Colitis cystica profunda mimicking mucinous adenocarcinoma of the rectum diagnosed by endoscopic submucosal dissection. 61
32818983 2021
9
Primary Invasive Mucinous Adenocarcinoma of the Lung: Prognostic Value of CT Imaging Features Combined with Clinical Factors. 61
33236544 2021
10
Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. 61
33796913 2021
11
Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. 61
33607478 2021
12
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix. 61
32641744 2021
13
Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section. 61
33197404 2021
14
[A Case of Gastric Cancer Which Caused Severe Anemia(Hemoglobin 1.8 g/dL)]. 61
33790158 2021
15
Nanog maintains stemness of Lkb1-deficient lung adenocarcinoma and prevents gastric differentiation. 61
33439550 2021
16
Current Microsatellite Instability Testing in Management of Colorectal Cancer. 61
32888812 2021
17
Clinicopathological characteristics and survival outcomes for patients with mucinous colorectal cancer liver metastases undergoing hepatic resection: A systematic review and meta-analysis. 61
33750573 2021
18
A case report of multiple bilateral breast metastases after colorectal cancer. 61
33743246 2021
19
Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. 61
33685728 2021
20
Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis. 61
33665720 2021
21
Combined fibrinogen-to-pre-albumin ratio and carbohydrate antigen 19-9 score is a promising metric to predict progression of metastatic colorectal mucinous adenocarcinoma. 61
33734488 2021
22
A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung. 61
33478856 2021
23
Incidental Finding of Primary Mucinous Adenocarcinoma of Gall Bladder: a Histopathological Diagnosis. 61
32529395 2021
24
Treating the treatment: chemotherapy-induced multi-organ toxicity. 61
33722912 2021
25
Clinicopathological characteristics and survival in lung signet ring cell carcinoma: a population-based study. 61
33596400 2021
26
Invasive mucinous adenocarcinoma of the lung arising in a type 1 congenital pulmonary airway malformation in a 68-year-old patient: a case report. 61
31262240 2021
27
Acinar with ductal and mucinous adenocarcinoma of prostate cancer complicated with lung metastasis: a case report and literature review. 61
32576002 2021
28
Is 99m Tc bone scintigraphy necessary in the preoperative workup for patients with cT1N0 subsolid lung cancer? A prospective multicenter cohort study. 61
33210466 2021
29
The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. 61
33634422 2021
30
A case of Endometrioid endometrial adenocarcinoma with synchronous low-grade Appendiceal mucinous neoplasm and Pseudomyxoma peritonei. 61
33605928 2021
31
A case of primary adenocarcinoma of the seminal vesicle treated by total laparoscopic pelvic exenteration. 61
32854127 2021
32
Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database. 61
33568091 2021
33
Mucinous Adenocarcinoma With Intrapulmonary Metastasis Harboring KRAS and GNAS Mutations Arising in Congenital Pulmonary Airway Malformation. 61
33609098 2021
34
Comparative study of imaging and pathological evaluation of pneumonic mucinous adenocarcinoma. 61
33552246 2021
35
Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. 61
32810914 2021
36
Salivary Mucinous Adenocarcinoma Is a Histologically Diverse Single Entity With Recurrent AKT1 E17K Mutations: Clinicopathologic and Molecular Characterization With Proposal for a Unified Classification. 61
33739781 2021
37
Cervical Adenoma Malignum in Third Trimester Pregnancy. 61
33506174 2021
38
Pseudomyxoma pleurii: unusual location of a rare disease. 61
33294092 2021
39
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. 61
32852072 2021
40
Mapping of colorectal carcinoma diseases with activation of Wnt/beta-catenin signalling pathway using hierarchical clustering approach. 61
33441391 2021
41
Chemotherapy for Non-Small Cell Lung Cancer in the Intensive Care Unit. 61
33383487 2021
42
The expression of trefoil factor 3 is related to histologic subtypes and invasiveness in lung adenocarcinoma. 61
33281974 2021
43
Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy. 61
32924067 2021
44
A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort. 61
33738248 2021
45
Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma. 61
33738258 2021
46
Risk of Second Primary Malignancies Based on the Histological Subtypes of Colorectal Cancer. 61
33777813 2021
47
Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: a retrospective descriptive study. 61
33509224 2021
48
Clinical, endoscopic and histological profile of colorectal cancers seen on colonoscopy in Kano, North-Western Nigeria. 61
33642320 2021
49
A Case Report: Cutaneous Metastasis of Advanced Rectal Cancer with BRAF Mutation. 61
33603403 2021
50
Late Development of Metastatic Ovarian Mucinous Adenocarcinoma From Primary Gallblader Adenocarcinoma and High-grade Dysplasia. 61
32897957 2021

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 TP53 NRG1 MUC1 KRAS HNF4A ESR1
2
Show member pathways
12.76 TP53 MLH1 KRAS ERBB2 EGFR CDKN2A
3
Show member pathways
12.68 TP53 NRG1 KRAS ERBB2 EGFR
4
Show member pathways
12.66 TP53 NRG1 KRAS ESR1 ERBB2
5
Show member pathways
12.61 PGR KRT20 KRAS ESR1 EGFR
6 12.58 TP53 MLH1 KRAS ESR1 ERBB2 EGFR
7
Show member pathways
12.54 TP53 NRG1 KRAS ERBB2 EGFR
8
Show member pathways
12.47 TP53 KRAS ESR1 ERBB2 EGFR CDKN2A
9 12.45 TP53 KRAS ERBB2 EGFR CDKN2A
10
Show member pathways
12.35 NRG1 KRAS ERBB2 EGFR ALK
11
Show member pathways
12.27 NRG1 ESR1 ERBB2 EGFR
12
Show member pathways
12.26 TP53 NRG1 ERBB2 EGFR
13
Show member pathways
12.23 NRG1 KRAS ERBB2 EGFR
14 12.19 TP53 KRAS ESR1 ERBB2 EGFR
15
Show member pathways
12.17 NRG1 MUC1 KRAS ERBB2 EGFR
16 12.12 TP53 MLH1 KRAS EGFR
17 12.07 TP53 KRAS ESR1 EGFR
18 12.05 NRG1 ERBB2 EGFR ALK
19
Show member pathways
11.96 NRG1 KRAS ERBB2 EGFR
20
Show member pathways
11.94 TP53 PGR MLH1 KRAS ESR1 ERBB2
21 11.87 TP53 KRAS ERBB2 CDKN2A
22 11.84 TP53 KRAS EGFR CDKN2A
23 11.62 TP53 MLH1 ERBB2 CDKN2A
24 11.58 TP53 KRAS ERBB2 EGFR
25 11.53 TP53 HNF4A CDKN2A
26 11.49 TP53 EGFR CDKN2A
27
Show member pathways
11.47 PGR NRG1 KRAS ESR1 ERBB2 EGFR
28 11.46 KRAS ESR1 EGFR
29 11.43 NRG1 KRAS ERBB2 EGFR
30 11.42 TP53 KRAS ERBB2 EGFR CDKN2A
31 11.18 KRAS ERBB2 EGFR

GO Terms for Mucinous Adenocarcinoma

Cellular components related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.8 TP53 PGR NKX2-1 MUC1 HNF4A ESR1
2 protein-containing complex GO:0032991 9.63 TP53 ESR1 EGFR CDX2 CDKN2A ALK
3 apical plasma membrane GO:0016324 9.02 NRG1 MUC1 ERBB2 EGFR CEACAM5
4 intrinsic component of Golgi membrane GO:0031228 8.96 CHST5 CHST4

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.15 TP53 PGR NKX2-1 HNF4A ESR1 ERBB2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 TP53 PGR NKX2-1 HNF4A ESR1 EGFR
3 positive regulation of protein kinase B signaling GO:0051897 9.78 NRG1 ESR1 ERBB2 EGFR
4 positive regulation of cell growth GO:0030307 9.77 NRG1 ERBB2 EGFR
5 positive regulation of kinase activity GO:0033674 9.74 ERBB2 EGFR ALK
6 Ras protein signal transduction GO:0007265 9.73 TP53 KRAS CDKN2A
7 positive regulation of MAP kinase activity GO:0043406 9.69 KRAS ERBB2 EGFR
8 O-glycan processing GO:0016266 9.67 MUC5AC MUC1 CHST4
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 NRG1 ERBB2 EGFR ALK
10 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.59 TP53 ESR1
11 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.58 TP53 ESR1
12 intracellular steroid hormone receptor signaling pathway GO:0030518 9.58 PGR ESR1
13 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.52 TP53 MUC1
14 regulation of cell motility GO:2000145 9.5 NRG1 ERBB2 EGFR
15 negative regulation of ERBB signaling pathway GO:1901185 9.46 ERBB2 EGFR
16 protein sulfation GO:0006477 9.43 CHST5 CHST4
17 oligodendrocyte differentiation GO:0048709 9.43 NRG1 NKX2-1 ERBB2
18 positive regulation of gene expression GO:0010628 9.43 TP53 NRG1 NKX2-1 KRAS ERBB2 CDKN2A
19 negative regulation of immature T cell proliferation in thymus GO:0033088 9.4 ERBB2 CDKN2A
20 ERBB2 signaling pathway GO:0038128 9.33 NRG1 ERBB2 EGFR
21 positive regulation of transcription, DNA-templated GO:0045893 9.17 TP53 NKX2-1 HNF4A ESR1 EGFR CDX2

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.03 TP53 PGR KRAS ESR1 ERBB2 EGFR
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 10.02 TP53 PGR NKX2-1 MUC1 HNF4A ESR1
3 sequence-specific DNA binding GO:0043565 9.92 PGR NKX2-1 HNF4A ESR1 CDX2
4 chromatin binding GO:0003682 9.91 TP53 MLH1 HNF4A ESR1 EGFR
5 DNA-binding transcription factor activity GO:0003700 9.73 TP53 PGR NKX2-1 HNF4A ESR1 CDX2
6 ATPase binding GO:0051117 9.72 PGR ESR1 EGFR
7 p53 binding GO:0002039 9.67 TP53 MUC1 CDKN2A
8 MDM2/MDM4 family protein binding GO:0097371 9.54 TP53 CDKN2A
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 ERBB2 EGFR ALK
10 nuclear receptor activity GO:0004879 9.5 PGR HNF4A ESR1
11 nitric-oxide synthase regulator activity GO:0030235 9.46 ESR1 EGFR
12 N-acetylglucosamine 6-O-sulfotransferase activity GO:0001517 9.4 CHST5 CHST4
13 ErbB-3 class receptor binding GO:0043125 9.16 NRG1 ERBB2
14 steroid hormone receptor activity GO:0003707 9.13 PGR HNF4A ESR1
15 enzyme binding GO:0019899 9.1 TP53 PGR NKX2-1 MLH1 ESR1 EGFR

Sources for Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....